Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
作者： Rosa Lapalombella , Bo Yu , Georgia Triantafillou , Qing Liu , Jonathan P. Butchar
DOI: 10.1182/BLOOD-2008-01-133108
关键词:
摘要: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL). The anti-CD20 antibody rituximab active in CLL and represents rational to combine with lenalidomide. We therefore examined whether lenalidomide combined direct apoptosis ADCC cells. In contrast previous reports using CD20-positive lymphoma cell lines, down-regulated CD20 surface antigen expression patient cells via enhanced internalization, without influencing transcription. internalization delivery of oligonucleotide incorporated into immunoliposomes. addition, down-modulation by was accompanied diminished rituximab-mediated ADCC. These observations suggest need alternative sequencing strategies avoid antagonism between CLL. they might be useful enhance targeted RNAi-based therapies immunoliposomes B-cell malignancies.
ashpublications.org
bloodjournal.org参考文章(40)
Kenneth J. Livak, Thomas D. Schmittgen, ANALYSIS OF RELATIVE GENE EXPRESSION DATA USING REAL-TIME QUANTITATIVE PCR AND THE 2(-DELTA DELTA C(T)) METHOD Methods. ,vol. 25, pp. 402- 408 ,(2001) , 10.1006/METH.2001.1262
Yu-Tzu Tai, Xian-Feng Li, Laurence Catley, Rory Coffey, Iris Breitkreutz, Jooeun Bae, Weihua Song, Klaus Podar, Teru Hideshima, Dharminder Chauhan, Robert Schlossman, Paul Richardson, Steven P. Treon, Iqbal S. Grewal, Nikhil C. Munshi, Kenneth C. Anderson, Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40–Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications Cancer Research. ,vol. 65, pp. 11712- 11720 ,(2005) , 10.1158/0008-5472.CAN-05-1657
Azra Raza, Eric Feldman, Bayard Powell, Peter Greenberg, Deborah Thomas, Richard Stone, Craig Reeder, Kenton Wride, John Patin, Michele Schmidt, Jerome Zeldis, Robert Knight, Alan List, Gordon Dewald, John Bennett, Aristotle Giagounidis, Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion The New England Journal of Medicine. ,vol. 355, pp. 1456- 1465 ,(2006) , 10.1056/NEJMOA061292
Francisco J. Hernandez-Ilizaliturri, Nishitha Reddy, Beata Holkova, Edris Ottman, Myron S. Czuczman, Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model Clinical Cancer Research. ,vol. 11, pp. 5984- 5992 ,(2005) , 10.1158/1078-0432.CCR-05-0577
Valeria Facchinetti, Massimiliano Manganini, Gianmaria Borleri, Josée Golay, Alessandro Rambaldi, Rosanna Gramigna, Martino Introna, Raewyn Broady, Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2 Haematologica. ,vol. 88, pp. 1002- 1012 ,(2003) , 10.3324/%X
Asher Chanan-Khan, Carl W Porter, Immunomodulating drugs for chronic lymphocytic leukaemia Lancet Oncology. ,vol. 7, pp. 480- 488 ,(2006) , 10.1016/S1470-2045(06)70723-9
Asher Chanan-Khan, Kena C. Miller, Laurie Musial, David Lawrence, Swaminathan Padmanabhan, Kenichi Takeshita, Carl W. Porter, David W. Goodrich, Zale P. Bernstein, Paul Wallace, David Spaner, Alice Mohr, Catriona Byrne, Francisco Hernandez-Ilizaliturri, Cynthia Chrystal, Petr Starostik, Myron S. Czuczman, Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study Journal of Clinical Oncology. ,vol. 24, pp. 5343- 5349 ,(2006) , 10.1200/JCO.2005.05.0401
Paul G. Richardson, Robert L. Schlossman, Edie Weller, Teru Hideshima, Constantine Mitsiades, Faith Davies, Richard LeBlanc, Laurence P. Catley, Deborah Doss, Kathleen Kelly, Mary McKenney, Julie Mechlowicz, Andrea Freeman, Reggie Deocampo, Rebecca Rich, Joan J. Ryoo, Dharminder Chauhan, Kathe Balinski, Jerome Zeldis, Kenneth C. Anderson, Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood. ,vol. 100, pp. 3063- 3067 ,(2002) , 10.1182/BLOOD-2002-03-0996
M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Léger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, N. Ketterer, M. Wernli, T. Cerny, S.-F. Hsu Schmitz, Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) Annals of Oncology. ,vol. 16, pp. 1675- 1682 ,(2005) , 10.1093/ANNONC/MDI320
Alan G Ramsay, Amy J Johnson, Abigail M Lee, Güllü Gorgün, Rifca Le Dieu, William Blum, John C Byrd, John G Gribben, None, Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug Journal of Clinical Investigation. ,vol. 118, pp. 2427- 2437 ,(2008) , 10.1172/JCI35017